Investors rotating into cheaper stocks with more upside should ultimately benefit Rocket Lab and AST SpaceMobile. Both have already suffered major drawdowns. x.com 

Good SpaceX earnings could help Rocket Lab lead the new-space sector higher with a rally as violent as its capitulation. Rocket Lab is the sector leader outside SpaceX; its RSI is extremely oversold, the lower Bollinger band is overstretched and MACD's negative divergence is subsiding. Three upside gaps lie at $55.25-59.18, $64.22-65.71 and $73.11-74.76. The highest should fill before year-end, though the exact date is hard to predict. x.com  x.com 

Rocket Lab still looks ridiculously expensive at 29 times forward sales against SpaceX at 22 times, even after a 65% fall. At 22 times, Rocket Lab would be roughly $38, and SpaceX would still be the pick. SpaceX also has better forward guidance; Rocket Lab's negative adjusted EBITDA makes sales multiples the valuation yardstick. x.com  x.com  x.com  x.com 

Rocket Lab's revenue growth is about double SpaceX's at a similar valuation, making it the better buy. Its much lower revenue base also lets it grow faster for longer. x.com 

Rocket Lab is a great company worth owning at a discount, and its elevated volatility pays well to wait for one. It is the only US public rocket company at scale, its backlog grows every quarter and revenue is up 55% year over year. Its implied volatility is among the highest in the space sector, with IV rank above 60%, while weekly EMA clouds are green and daily RSI just hit 44. x.com 

Rocket Lab's $3B at-the-market offering shows it needs investor cash because it has no real earnings or path to profitability, and it should have raised $10-15B while the window lasts. Selling stock at such a high valuation is the only way to sustain the next 18-24 months, and the coming SpaceX IPO will most likely be the sell event for the entire space sector. x.com  x.com 

Rocket Lab should see money flow back once SpaceX's rich valuation corrects. SpaceX's listing day could be sell-the-news, pulling Rocket Lab back to $90-100 at most, but at roughly 90-100x sales it is valued about the same as SpaceX at around 115x. With expected Nasdaq inclusion on June 22 and capital rotating from SpaceX into quality space stocks, a lower-high move toward the $130 target banks just raised is possible. x.com  x.com 

Rocket Lab looks set for a major comeback as SpaceX, the main reason the space sector sold off, starts performing better. The same failed head-and-shoulders pattern that preceded Rocket Lab's parabolic 2024 run has formed again, with the stock bottoming exactly at the neckline, and SpaceX's improvement is already showing in other space stocks. x.com 

Rocket Lab makes little sense to buy over SpaceX, whose IPO is priced at a similar share price with far larger revenue. SpaceX targets $135 a share with $18.7B of revenue, while Rocket Lab trades at $115 with $600M. x.com 

Rocket Lab has legitimate buying behind it, visible in weekly volume, and could take out $100 this time, perhaps after a pullback, helped by the SpaceX IPO pump. Prior highs around $98-100 are the resistance to clear. x.com